Skip to main content
. 2020 Aug 14;26(10):1597–1606. doi: 10.1093/ibd/izaa209

FIGURE 1.

FIGURE 1.

Serum miRNA expression in validation cohorts. Serum was obtained from patients at baseline and after treatment with either anti-TNF-α or GCs. A, B, Patients were treated with anti-TNF-α therapy for a median of 53.5 days (post-treatment sample drawn before third or fourth dose), then serum miRNAs assayed by real-time quantitative reverse transcription PCR (qRT-PCR) pre-and post-therapy. To illustrate expression levels in a healthy baseline state, non-IBD controls are also presented as a phenotypic healthy control reference. The miRNA expression is presented as fold expression relative to healthy control levels. Seven candidate miRNAs identified in the discovery cohort were assayed (A); in addition, 4 miRNA candidates from a prior study were assayed (B). C, Patients were treated with GCs for a median of 8.5 days, then serum miRNAs assayed pre- and post-therapy by qRT-PCR. (#P ≤ 0.05, ###P ≤ 0.005, ####P ≤ 0.0005, t test of healthy control reference vs baseline pre-IFX, n = 8 per group; *P ≤ 0.05, **P ≤ 0.01, paired 1-tailed t test comparing post-treatment to baseline in direction of discovery, n = 8 per group.)